federal_register: 2011-31556
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| document_number | title | type | abstract | publication_date | pub_year | pub_month | html_url | pdf_url | agency_names | agency_ids | excerpts | regulation_id_numbers |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2011-31556 | Prospective Grant of Exclusive License: Use of Agents Targeting Thrombospondin-1 and CD47 To Treat Radiation-Induced Damage and Enhance the Effectiveness of Radiotherapy in Cancer Patients | Notice | This is a notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is contemplating the grant of a worldwide exclusive license, to practice the inventions embodied in U.S. Provisional Patent Application No. 60/850,132, filed October 6, 2006, now abandoned (HHS Ref. No. E-227-2006/0-US-01); U.S. Provisional Patent Application No. 60/864,153, filed November 02, 2006, now abandoned (HHS Ref. No. E-227-2006/1-US-01); U.S. Provisional Patent Application No. 60/888,754, filed February 07, 2007, now abandoned (HHS Ref. No. E-227-2006/2-US-01); U.S. Provisional Patent Application No. 60/910,549, filed April 06, 2007, now abandoned (HHS Ref. No. E-227-2006/3-US-01); U.S. Provisional Patent Application No. 60/956,375, filed August 16, 2007, now abandoned (HHS Ref. No. E-227- 2006/4-US-01); PCT Patent Application No. PCT/2007/080647, filed October 5, 2007, now abandoned (HHS Ref. No. E-227-2006/5-PCT-01); U.S. Patent Application No. 12/444,364, filed April 3, 2009 (HHS Ref. No. E- 227-2006/5-US-02); Canadian Patent Application No. 2,665,287, filed October 5, 2007 (HHS Ref. No. E-227-2006/5-CA-03); Australian Patent Application No. 2007319576, filed October 5, 2007 (HHS Ref. No. E-227- 2006/5-AU-04); European Patent Application No. 07868382.8, filed October 5, 2007 (HHS Ref. No. E-227-2006/5-EP-05); U.S. Provisional Patent Application No. 61/086,991, filed August 7, 2008, now abandoned (HHS Ref. No. E-153-2008/0-US-01); PCT Patent Application No. PCT/2009/ 052902, filed August 5, 2009, now abandoned (HHS Ref. No. E-153-2008/0- PCT-02); U.S. Patent Application No. 13/057,447, filed February 3, 2011 (HHS Ref. No. E-153-2008/0-US-06); Canadian Patent Application No. 2732102 filed August 5, 2009 (HHS Ref. No. E-153-2008/0-CA-043); Australian Patent Application No. 2009279676, filed August 5, 2009 (HHS Ref. No. E-153-2008/0-AU-03); and European Patent Application No. 09791202.6, filed August 5, 2009 (HHS Ref. No. E-153-2008/0-EP-08), entitled "Prevention of Tissue Ischemia, Related Methods and Compositions," and "Radioprotectants Targeting Thrombospondin-1 and CD47," to Radiation Control Technologies, Inc., a company incorporated under the laws of the State of Delaware having its headquarters in Rockville, Maryland. The United States of America is the assignee of the rights of the above inventions. The prospective exclusive license territory may be "worldwide," and the field of use may be limited to: (1) The use of morpholino oligonucleotides that reduce expression of CD47 in combination with radiotherapy, to treat or prevent cancers in humans; and (2) the use of morpholino oligonucleotides that reduce expression of CD47 to treat or prevent radiation exposure damage in humans. | 2011-12-08 | 2011 | 12 | https://www.federalregister.gov/documents/2011/12/08/2011-31556/prospective-grant-of-exclusive-license-use-of-agents-targeting-thrombospondin-1-and-cd47-to-treat | https://www.govinfo.gov/content/pkg/FR-2011-12-08/pdf/2011-31556.pdf | Health and Human Services Department; National Institutes of Health | 221,353 | This is a notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is contemplating the grant of a worldwide exclusive license, to practice... |